Print Page | Close Window


May 23, 2018 - 4:02 p.m.
Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6
Printer Friendly Version 
May 15, 2018 - 10:58 a.m.
U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
Printer Friendly Version 
May 15, 2018 - 8:32 a.m.
Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline
Printer Friendly Version 
May 09, 2018 - 4:31 p.m.
Harish Manwani Joins Gilead Sciences’ Board of Directors
Printer Friendly Version 
May 08, 2018 - 9:02 a.m.
Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16
Printer Friendly Version 
May 01, 2018 - 4:03 p.m.
Gilead Sciences Announces Second Quarter 2018 Dividend
Printer Friendly Version 
May 01, 2018 - 4:03 p.m.
Gilead Sciences Announces First Quarter 2018 Financial Results
Printer Friendly Version 
April 30, 2018 - 4:06 p.m.
Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases
Printer Friendly Version 
April 27, 2018 - 6:37 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
Printer Friendly Version 
April 17, 2018 - 5:02 p.m.
Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018
Printer Friendly Version 
April 13, 2018 - 10:15 a.m.
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018
Printer Friendly Version 
March 12, 2018 - 9:02 a.m.
Gilead Sciences’ Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
Printer Friendly Version 
March 05, 2018 - 4:01 p.m.
Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen
Printer Friendly Version 
March 05, 2018 - 12:08 p.m.
Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine
Printer Friendly Version 
March 04, 2018 - 4:20 p.m.
Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys
Printer Friendly Version 
February 22, 2018 - 5:01 p.m.
Gilead Sciences Announces Senior Management Change
Printer Friendly Version 
February 22, 2018 - 7:01 a.m.
Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer
Printer Friendly Version 
February 08, 2018 - 4:02 p.m.
Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21
Printer Friendly Version 
February 07, 2018 - 2:22 p.m.
U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Printer Friendly Version 
February 06, 2018 - 4:02 p.m.
Gilead Sciences Announces 10 Percent Increase in First Quarter 2018 Dividend
Printer Friendly Version 
February 06, 2018 - 4:01 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results
Printer Friendly Version 
February 01, 2018 - 4:05 p.m.
Jacqueline K. Barton, Ph.D., Joins Gilead Sciences’ Board of Directors
Printer Friendly Version 
January 23, 2018 - 4:02 p.m.
Gilead Sciences to Release Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 6, 2018
Printer Friendly Version 
January 18, 2018 - 8:31 a.m.
Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma
Printer Friendly Version